Is Bliss GVS Pharma a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a average quality company .

Is Bliss GVS Pharma undervalued or overvalued?

The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Bliss GVS Pharma share price return in the past 10 years?

Bliss GVS Pharma Ltd share price has appreciated 7.8% annually (CAGR) over the past ten years.

Is Bliss GVS Pharma a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Bliss GVS Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Bliss GVS Pharma Ltd - Stock Valuation and Financial Performance

Name: Bliss GVS Pharma
Brand: Bliss GVS Pharma

BSE: 506197 | NSE: BLISSGVS | Pharmaceuticals & Drugs | Small Cap

Place order

Bliss GVS Pharma Share Price

₹129.70 5.50 4.43%
as on 20-Sep'24 16:01

10 Year X-Ray of Bliss GVS Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	23.9%	23.4%	19.3%	15.6%	18.8%	17.8%	12%	14.7%	12.9%	7.4%	-
Value Creation Index ⓘ	0.7	0.7	0.4	0.1	0.3	0.3	-0.1	0.1	-0.1	-0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	313	326	348	298	427	442	466	636	598	605	645
Sales YoY Gr.	-	4.3%	6.6%	-14.4%	43.2%	3.6%	5.3%	36.7%	-6%	1.2%	-
Adj EPS ⓘ	5.1	5.4	5.8	5.2	5.4	7	6	7.5	5.6	6.6	6
YoY Gr.	-	6.9%	6.9%	-10.8%	4.3%	29.6%	-13.2%	23.3%	-24.7%	16.8%	-
BVPS (₹) ⓘ	35.7	41.9	47.7	52.5	58.5	66.2	72.3	81.2	89.1	93.7	95.2
Adj Net Profit ⓘ	52.1	55.7	59.5	53.2	55.3	71.8	62.3	77.3	58.4	68.6	63
Cash Flow from Ops. ⓘ	15.4	59.6	38.5	22.7	48.3	63.2	67	114	43.8	126	-
Debt/CF from Ops. ⓘ	5.9	1.4	2	4.1	1.5	1.4	1.3	0.8	1.8	0.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.6%	7.3%	9.2%	1.2%
Adj EPS ⓘ	2.9%	4.1%	2.7%	16.8%
BVPSⓘ	11.3%	9.9%	9%	5.1%
Share Price	7.8%	4.4%	5%	41.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	15.3	13.9	12.9	10.3	9.7	11.2	8.7	9.6	6.5	7.1	6.3
Op. Profit Mgn % ⓘ	27.6	29.6	29	29.7	22.4	22.7	19.7	17.2	15.1	17.4	19
Net Profit Mgn % ⓘ	16.7	17.1	17.1	17.9	13	16.2	13.4	12.1	9.8	11.3	9.7
Debt to Equity ⓘ	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	-
Working Cap Days ⓘ	497	527	533	621	442	443	471	372	419	401	206
Cash Conv. Cycle ⓘ	154	206	206	270	269	307	293	212	233	242	173

Recent Performance Summary

Sales growth is good in last 4 quarters at 17.47%

Return on Equity has declined versus last 3 years average to 6.30%

Sales growth has been subdued in last 3 years 9.16%

Net Profit has been subdued in last 3 years 2.74%

Latest Financials - Bliss GVS Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	6	7.8
TTM Sales (₹ Cr.)	645	794
BVPS (₹.) ⓘ	95.2	93.4
Reserves (₹ Cr.) ⓘ	990	972
P/BV ⓘ	1.36	1.39
PE ⓘ	21.80	16.74

From the Market
52 Week Low / High (₹)	77.65 / 148.95
All Time Low / High (₹)	0.04 / 230.00
Market Cap (₹ Cr.)	1,364
Equity (₹ Cr.)	10.5
Face Value (₹)	1
Industry PE ⓘ	47.6

Management X-Ray of Bliss GVS Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Bliss GVS Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Bliss GVS Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	313	326	348	298	427	442	466	636	598	605
Operating Expenses ⓘ	227	230	247	209	333	342	374	527	508	500
Manufacturing Costs	30	27	6	6	8	11	14	18	17	26
Material Costs	116	114	167	146	225	237	253	344	315	299
Employee Cost	17	22	25	26	34	44	59	65	73	83
Other Costs ⓘ	63	67	49	31	67	50	48	100	104	92
Operating Profit ⓘ	86	97	101	88	93	100	91	109	90	106
Operating Profit Margin (%)	27.5%	29.6%	28.9%	29.7%	21.8%	22.7%	19.6%	17.2%	15.1%	17.4%
Other Income ⓘ	21	23	9	11	36	37	19	33	51	35
Interest ⓘ	11	14	9	7	3	7	6	4	10	6
Depreciation ⓘ	5	6	6	6	6	9	14	14	15	24
Exceptional Items ⓘ	0	0	0	0	0	0	0	3	0	-41
Profit Before Tax ⓘ	91	100	95	87	120	122	91	126	116	70
Tax ⓘ	31	35	36	30	46	29	24	34	30	20
Profit After Tax	60	66	59	57	74	92	68	93	85	51
PAT Margin (%)	19.2%	20.1%	17.0%	19.1%	17.4%	20.9%	14.5%	14.6%	14.3%	8.4%
Adjusted EPS (₹)	5.8	6.4	5.7	5.5	7.2	9.0	6.5	8.9	8.2	4.8
Dividend Payout Ratio (%)	12%	8%	10%	18%	14%	6%	8%	6%	6%	10%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	368	432	492	541	603	683	746	841	928	981
Share Capital ⓘ	10	10	10	10	10	10	10	10	10	10
Reserves ⓘ	358	422	481	531	593	673	735	831	918	970
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	59	62	74	88	67	71	68	65	66	46
Long Term Debt	30	12	12	6	31	36	32	23	41	35
Short Term Debt	28	50	61	83	37	36	35	41	25	11
Trade Payables	50	35	64	35	31	56	67	84	76	54
Others Liabilities ⓘ	78	168	37	29	35	45	65	90	70	67
Total Liabilities ⓘ	555	697	666	694	736	855	946	1,080	1,140	1,148
Fixed Assets
Gross Block	120	123	81	83	93	202	211	270	385	413
Accumulated Depreciation	38	44	6	11	15	23	37	45	60	84
Net Fixed Assetsⓘ	82	79	75	72	78	179	174	224	325	330
CWIP ⓘ	0	2	2	0	43	0	2	22	3	8
Investmentsⓘ	19	21	22	19	19	19	18	18	18	19
Inventories	23	22	28	40	55	61	84	90	74	89
Trade Receivables	211	251	239	283	342	405	349	409	399	400
Cash Equivalents	47	57	84	70	93	87	120	149	85	169
Others Assetsⓘ	174	266	216	209	105	105	199	167	236	134
Total Assets ⓘ	555	697	666	694	736	855	946	1,080	1,140	1,148

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	15	60	38	23	48	63	67	114	44	126
PBT ⓘ	91	100	95	87	120	122	91	124	116	111
Adjustment ⓘ	15	7	28	1	3	3	41	35	41	44
Changes in Working Capital ⓘ	-51	-28	-47	-29	-26	-30	-43	-14	-76	-0
Tax Paid ⓘ	-40	-20	-37	-36	-50	-32	-23	-30	-38	-29
Cash Flow From Investing Activity ⓘ	-21	-10	-29	16	-68	-60	-62	-92	-13	-110
Capex	-29	-5	-3	-1	-59	-67	-8	-73	-94	-38
Net Investments	0	-1	-32	3	0	0	0	3	0	0
Others ⓘ	7	-3	5	14	-9	7	-54	-22	81	-71
Cash Flow From Financing Activityⓘ	-31	-35	-15	-22	9	-6	-12	-13	-26	-21
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	2	2	2
Net Proceeds from Borrowing ⓘ	0	0	0	0	24	13	2	-5	-16	-10
Interest Paid ⓘ	-10	-11	-9	-8	-3	-4	-6	-2	-6	-5
Dividend Paid ⓘ	-6	-6	-5	-6	-12	-12	-6	-5	-5	-5
Others ⓘ	-15	-18	0	-8	0	-2	-2	-2	-1	-3
Net Cash Flow ⓘ	-37	14	-6	17	-11	-3	-6	9	5	-4

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	17.62	16.41	12.8	11.04	13	14.36	9.45	11.68	9.66	5.31
ROCE (%)	23.91	23.43	19.25	15.6	18.8	17.75	12.02	14.68	12.89	7.36
Asset Turnover Ratio	0.54	0.52	0.51	0.44	0.6	0.56	0.52	0.63	0.54	0.53
PAT to CFO Conversion(x)	0.25	0.91	0.64	0.4	0.65	0.68	0.99	1.23	0.52	2.47
Working Capital Days
Receivable Days	228	257	255	319	267	308	295	217	246	241
Inventory Days	25	25	26	42	40	48	57	50	50	49
Payable Days	172	136	108	124	54	67	88	80	93	79

Bliss GVS Pharma Ltd Stock News

Bliss GVS Pharma Ltd FAQs

What is the share price of Bliss GVS Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Bliss GVS Pharma on 20-Sep-2024 16:01 is ₹129.7.

What is the market cap of Bliss GVS Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Sep-2024 16:01 the market cap of Bliss GVS Pharma stood at ₹1,363.7.

What is the P/E ratio of Bliss GVS Pharma?

The latest P/E ratio of Bliss GVS Pharma as of 20-Sep-2024 16:01 is 21.80.

What is the P/B ratio of Bliss GVS Pharma?

The latest P/B ratio of Bliss GVS Pharma as of 20-Sep-2024 16:01 is 1.36.

What is the 52-week high and low of Bliss GVS Pharma?

The 52-week high of Bliss GVS Pharma is ₹148.9 and the 52-week low is ₹77.65.

What is the TTM revenue of Bliss GVS Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bliss GVS Pharma is ₹645.4 ( Cr.) .

About Bliss GVS Pharma Ltd

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
2011: EU-GMP approval to the manufacturing facility for suppository facility.
2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
2017: Setting up offices in South East Asian countries.
2018: Divestment from Bliss GVS Healthcare.
2019: Setting up of multi-dosage facility (Vevoor Plant).